Transgene

Transgene Net Tangible Assets

The Net Tangible Assets of Transgene (TNG.PA) as of Nov 18, 2026 is 15.14 M EUR. In the previous year, Net Tangible Assets was 15.53 M EUR — a change of -2.51% (lower).

Net Tangible Assets

15.14 MEUR

YoY

-2.51%

Last updated:

Net Tangible Assets of Transgene is 2024 15.14 M EUR. Net Tangible Assets of Transgene was 2023 15.53 M EUR. It decreases by -2.51% lower compared to the previous year.

The Transgene Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2017
27.84 M EUR
Jan 1, 2018
36.52 M EUR
Jan 1, 2019
65.55 M EUR
Jan 1, 2020
50.11 M EUR
Jan 1, 2021
67.12 M EUR
Jan 1, 2022
37.76 M EUR
Jan 1, 2023
15.53 M EUR
Jan 1, 2024
15.14 M EUR
The Transgene Net Tangible Assets history
YEARNet Tangible AssetsYoY
15.14 MEUR-2.51%
15.53 MEUR-58.87%
37.76 MEUR-43.73%
67.12 MEUR+33.94%
50.11 MEUR-23.56%
65.55 MEUR+79.50%
36.52 MEUR+31.18%
27.84 MEUR-39.59%
46.08 MEUR+76.81%
26.06 MEUR-63.18%
70.78 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Tangible Assets of Transgene is 15.14 M EUR in 2024.

Net Tangible Assets of Transgene changed from 15.53 M EUR to 15.14 M EUR, representing a -2.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Transgene since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Transgene

All Key Metrics — Transgene